Rchr
J-GLOBAL ID：202301003450112515
Update date: Mar. 02, 2024
Rai Kammei
Rai Kammei
Research theme for competitive and other funds (2)：
- 2021 - 2024 Evaluation of exercise tolerance with low-intensity exercise using wearable devices
- 2016 - 2019 Overcome resistance against EGFR molecular targeting drugs by siRNA
Papers (31)：
-
Takumi Kishimoto, Kenzo Okamoto, Shigeki Koda, Mariko Ono, Yumi Umeda, Shotaro Yamano, Tomoki Takeda, Kammei Rai, Katsuya Kato, Yasumitsu Nishimura, et al. Respiratory disease in workers handling cross-linked water-soluble acrylic acid polymer. PloS one. 2023. 18. 4. e0284837
-
Eri Ando, Takamasa Nakasuka, Toshio Kubo, Akihiko Taniguchi, Kiichiro Ninomiya, Yuka Kato, Eiki Ichihara, Kadoaki Ohashi, Kammei Rai, Katsuyuki Hotta, et al. Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western Japan. Internal medicine (Tokyo, Japan). 2022. 61. 3. 379-383
-
Sachi Okawa, Kammei Rai, Nobuharu Fujii, Yuka Gion, Kiichiro Ninomiya, Yuka Kato, Akihiko Taniguchi, Toshio Kubo, Eiki Ichihara, Kadoaki Ohashi, et al. Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related Disease. Internal medicine (Tokyo, Japan). 2021. 60. 17. 2831-2837
-
Hirohisa Kano, Eiki Ichihara, Hiromi Watanabe, Kazuya Nishii, Chihiro Ando, Takamasa Nakasuka, Kiichiro Ninomiya, Yuka Kato, Toshio Kubo, Kammei Rai, et al. SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non-small Cell Lung Cancer. Molecular cancer therapeutics. 2021. 20. 9. 1653-1662
-
Kazuya Nishii, Kadoaki Ohashi, Hiromi Watanabe, Go Makimoto, Takamasa Nakasuka, Hisao Higo, Kiichiro Ninomiya, Yuka Kato, Toshio Kubo, Kammei Rai, et al. Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression. Oncology letters. 2021. 22. 3. 639-639
ｍore...
MISC (32)：
-
大橋 圭明, 大川 祥, 頼 冠名, 木浦 勝行. 気管支鏡下再生検にて診断しえたIgG4関連疾患におけるEGFR変異肺腺癌合併の一例. 気管支学. 2021. 43. Suppl. S297-S297
-
Yuka Kato, Taku Noumi, Kazuhiko Saeki, Kiichiro Ninomiya, Toshio Kubo, Masanori Fujii, Kammei Rai, Eiki Ichihara, Kadoaki Ohashi, Masahiro Tabata, et al. Impact on second-line treatment after failure of immune checkpoint inhibitor (ICI) combination chemotherapy in extensive-disease small cell lung cancer: Experience of the Okayama Lung Cancer Study Group. JOURNAL OF CLINICAL ONCOLOGY. 2021. 39. 15
-
中須賀 崇匡, 大橋 圭明, 西井 和也, 平生 敦子, 大川 祥, 安東 千裕, 原 尚史, 狩野 裕久, 渡邉 洋美, 二宮 貴一朗, et al. Egfr改変肺癌マウスモデルを用いたAd-SGE-REICの抗腫瘍効果の検討. 肺癌. 2020. 60. 6. 528-528
-
加藤 有加, 堀田 勝幸, 二宮 貴一朗, 久保 寿夫, 頼 冠名, 市原 英基, 大橋 圭明, 田端 雅弘, 前田 嘉信, 木浦 勝行. 非小細胞肺癌領域における新規医薬品に基づく医薬品開発に係る臨床試験デザインについての検討. 肺癌. 2020. 60. 6. 534-534
-
渡邉 洋美, 狩野 裕久, 西井 和也, 原 尚史, 二宮 貴一朗, 加藤 有加, 久保 寿夫, 頼 冠名, 市原 英基, 大橋 圭明, et al. 患者由来ROS1肺癌細胞株の樹立とcrizotinib耐性機序の検討. 肺癌. 2020. 60. 6. 644-644
ｍore...
Professional career (1)：
- M.D.,Ph.D. (Okayama University)
Return to Previous Page
